相关实验视频
Updated: Jun 25, 2025
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
43.7K
治疗急性心力衰竭的血管扩张剂 - - 系统性综述与元分析
Jasmin D Lukoschewitz1, Kristina C Miger2, Anne Sophie O Olesen2
1Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen.
NEJM evidence
|May 28, 2024
概括
血管扩张剂并没有减少急性心力衰竭患者的全因死亡率. 然而,在这个系统性审查中,它们与气管管道输管的风险较低有关.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性心力衰竭 (AHF) 是一个重大的公共卫生挑战.
- 有效的AHF管理策略对于改善患者的治疗结果至关重要.
- 这项研究系统地审查了在AHF中使用血管扩展剂的证据.
研究的目的:
- 评估血管扩张剂在急性心力衰竭患者中的有效性和安全性.
- 通过元分析综合随机临床试验 (RCT) 的发现.
主要方法:
- 在多个数据库 (Medline,Embase等) 中进行全面的搜索. 进行了.执行了.
- 纳入标准集中在与标准护理,安慰剂或联合干预相比较血管扩展剂的RCT上.
- 主要结局是全因死亡率;次要结局包括严重不良事件 (SAE),气管管道输液和住院. 评估了偏见的风险.
主要成果:
- 分析包括46个RCT,涉及28374名患者.
- 血管扩张剂没有显著降低所有原因死亡率 (RR,0.95;95% CI,0.87-1.04).
- 没有观察到严重事故或住院时间的显著差异. 血管扩展剂的使用与气管管道输入减少有关 (RR,0.54;95% CI,0.30-0.99).
结论:
- 血管扩张剂似乎不能降低急性心力衰竭患者的全因死亡率.
- 这些发现表明,在降低气管管道输液率方面存在潜在的益处.
- 进一步的研究可能会澄清血管扩张剂在AHF治疗中的作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:23Antihypertensive Drugs: Vasodilators
505
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
505
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:16Antianginal Drugs: Nitrates and β-Blockers
575
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
575
01:26Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570